Search results for Canakinumab
Canakinumab Biosimilar – Anti-IL1B mAb – Research Grade, ProteoGenix, PX-TA1176
Description of Canakinumab Biosimilar - Anti-IL1B mAb - Research Grade Introduction Canakinumab Biosimilar, also known as Anti-IL1B mAb, is a monoclonal antibody that targets the inflammatory cytokine interleukin-1 beta (IL-1β). This biosimilar is a research grade version of Canakinumab, a FDA-approved therapeutic antibody used for the treatment of various inflammatory diseases. In this article, we will discuss the structure, activity, and potential applications of Canakinumab Biosimilar as a therapeutic antibody. Structure of Canakinumab Biosimilar Canakinumab Biosimilar is a fully human IgG1 monoclonal antibody that is produced through recombinant DNA technology. It is composed of two heavy chains and two light chains, each with a molecular weight of approximately 50 kDa. The antibody has a typical Y-shaped structure, with two antigen-binding fragments (Fab) and one crystallizable fragment (Fc). The Fab region is responsible for binding to IL-1β, while the Fc region mediates effector functions such as antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC). Mechanism of Action Canakinumab Biosimilar works by specifically binding to IL-1β and inhibiting its activity. IL-1β is a pro-inflammatory cytokine that plays a crucial role in the pathogenesis of various inflammatory diseases. By binding to IL-1β, Canakinumab Biosimilar prevents it from interacting with its receptors, thereby blocking its downstream signaling pathways. This leads to a decrease in the production of other pro-inflammatory cytokines and chemokines, ultimately reducing inflammation and associated symptoms. Potential Applications Canakinumab Biosimilar has shown promising results in pre-clinical studies for the treatment of various inflammatory diseases. It has been shown to be effective in reducing inflammation and symptoms in conditions such as rheumatoid arthritis, gout, and familial Mediterranean fever. In addition, Canakinumab Biosimilar has also been investigated as a potential treatment for cardiovascular diseases, as IL-1β has been implicated in the development of atherosclerosis and heart disease. Anti-inflammatory Effects One of the main applications of Canakinumab Biosimilar is in the treatment of inflammatory diseases. In a phase III clinical trial, Canakinumab was shown to be effective in reducing the frequency of gout flares in patients with gout. It has also been studied in patients with rheumatoid arthritis, where it was found to improve symptoms and inhibit joint damage. These results suggest that Canakinumab Biosimilar may be a promising therapeutic option for various inflammatory conditions. Cardiovascular Disease Canakinumab Biosimilar has also been investigated for its potential in reducing the risk of cardiovascular events. In a large-scale clinical trial, Canakinumab was shown to significantly reduce the risk of recurrent cardiovascular events in patients with a history of heart attack. This effect was independent of its anti-inflammatory properties, suggesting that Canakinumab may have additional cardioprotective mechanisms. Future Directions As a research grade version of Canakinumab, Canakinumab Biosimilar has the potential to be used in various pre-clinical studies to further understand the role of IL-1β in different diseases. It can also be used as a comparator in clinical trials to evaluate the efficacy and safety of new therapeutic antibodies targeting IL-1β. In addition, the development of Canakinumab Biosimilar may also lead to a more affordable and accessible treatment option for patients with inflammatory diseases. Conclusion Canakinumab Biosimilar, a research grade version of Canakinumab, is a promising therapeutic antibody targeting IL-1β. Its specific binding and inhibitory effects on IL-1β make it a potential treatment option for various inflammatory diseases and cardiovascular conditions
Host
Reactivity
Applications
Conjugation
Canakinumab, Abbexa, abx831131
Canakinumab is a monoclonal antibody biosimilar expressed in CHO cells, targeting IL1B, for use in laboratory research applications. This product is not suitable for use as medicines or in human, therapeutic or diagnostic applications. Canakinumab is a recombinant, human anti-human-IL-1β monoclonal antibody that belongs to the IgG1/κ isotype subclass. It is expressed in a murine Sp2/0-Ag14 cell line and comprised of two 447- (or 448-) residue heavy chains and two 214-residue light chains, with a molecular mass of 145157 Daltons when deglycosylated. Both heavy chains of canakinumab contain oligosaccharide chains linked to the protein backbone at asparagine 298 (Asn 298). Canakinumab binds to human IL-1β and neutralizes its inflammatory activity by blocking its interaction with IL-1 receptors, but it does not bind IL-1alpha or IL-1 receptor antagonist (IL-1ra). Canakinumab is marketed under the brand name Ilaris and indicated for patients 4 years of age and older to treat Familial Cold Autoinflammatory Syndrome (FCAS) and Muckle-Wells Syndrome (MWS), which are both part of the Cryopyrin-Associated Periodic Syndromes (CAPS) as well as for patients 2 years of age and older to treat systemic juvenile idiopathic arthritis (SJIA). Clinical trials have established the administration of canakinumab every 2 weeks to be safe and effective, offering a considerable advantage over the existing treatment with the human IL-1 receptor antagonist, anakinra, which must be injected daily and which is often poorly tolerated by patients.
Host
Human
Reactivity
Human
Applications
ELISA, WB
Conjugation
Unconjugated
Canakinumab ELISA Kit, ProteoGenix, KPTX131
Description of Canakinumab ELISA Kit Canakinumab ELISA Kit: A Comprehensive Guide Introduction Canakinumab is a human monoclonal antibody that targets interleukin-1 beta (IL-1β), a pro-inflammatory cytokine involved in various inflammatory diseases. It is primarily used as a therapeutic agent for the treatment of rare auto-inflammatory disorders such as cryopyrin-associated periodic syndromes (CAPS) and systemic juvenile idiopathic arthritis (SJIA). The development of a Canakinumab ELISA kit has greatly facilitated the detection and quantification of this important therapeutic target. Structure of Canakinumab Canakinumab is a fully human IgG1 monoclonal antibody with a molecular weight of approximately 148 kDa. It is composed of two heavy chains and two light chains, each containing a variable and constant region. The variable region of Canakinumab specifically binds to IL-1β, preventing its interaction with its receptor and inhibiting its pro-inflammatory effects. ELISA Principle ELISA (enzyme-linked immunosorbent assay) is a widely used technique for the detection and quantification of various molecules, including antibodies and antigens. The Canakinumab ELISA kit utilizes the principle of sandwich ELISA, where the target molecule is captured between two specific antibodies. In this case, the IL-1β present in the sample is captured by the Canakinumab-coated plate and detected by a secondary antibody conjugated with an enzyme. The resulting color change is then measured and is proportional to the amount of IL-1β present in the sample. Application of Canakinumab ELISA Kit The Canakinumab ELISA kit has a wide range of applications in both research and clinical settings. It is primarily used for the quantification of Canakinumab levels in patient samples, allowing for the monitoring of drug efficacy and dosing optimization. Additionally, it can also be used to measure IL-1β levels in various biological samples, providing valuable insights into the inflammatory status of a patient. Monitoring Canakinumab Therapy Canakinumab ELISA kit is an essential tool for monitoring the efficacy of Canakinumab therapy in patients with CAPS and SJIA. By measuring the levels of Canakinumab in the blood, clinicians can determine if the drug is reaching therapeutic levels and adjust the dosage accordingly. This helps in optimizing treatment and ensuring better patient outcomes. Assessment of Inflammatory Disorders IL-1β is a key mediator of inflammation, and its levels are often elevated in various inflammatory disorders. Canakinumab ELISA kit can be used to measure IL-1β levels in biological samples, providing valuable information about the inflammatory status of a patient. This can aid in the diagnosis and monitoring of diseases such as rheumatoid arthritis, gout, and atherosclerosis. Research Applications The Canakinumab ELISA kit is also widely used in research studies to investigate the role of IL-1β in various diseases and to evaluate the efficacy of new anti-inflammatory therapies. It enables researchers to accurately measure Canakinumab levels in different biological samples, providing valuable insights into the mechanism of action of this therapeutic antibody. Conclusion The Canakinumab ELISA kit is an essential tool for the detection and quantification of Canakinumab and IL-1β in various biological samples. It has revolutionized the monitoring of Canakinumab therapy and has enabled researchers to gain a better understanding of the role of IL-1β in inflammatory diseases. With its high sensitivity and specificity, the Canakinumab ELISA kit is a valuable asset in the field of immunology and inflammation research.
Host
Reactivity
Applications
Conjugation
Canakinumab ELISA Kit, Abbexa, abx395020
Canakinumab ELISA Kit is a quantitative ELISA kit for detection of Canakinumab.Canakinumab (ACZ885, Ilaris) is a human anti-IL-1β monoclonal antibody developed by Novartis. its mode of action is based on the neutralization of 1β signaling, resulting in suppression of inflammation in patients with disorders of autoimmune origin. In June 2009 the drug was approved by the US Food and Drug Administration for the treatment of familial cold auto-inflammatory syndrome and Muckle-wells syndrome, which are inflammatory diseases related to cryopyrin-associated periodic syndromes. The drug is currently being evaluated for its potential in the treatment of rheumatoid arthritis, systemic-onset juvenile idiopathic arthritis, chronic obstructive pulmonary disease, type 1 and 2 diabetes and ocular diseases. Reports from clinical trials suggest that canakinumab is well-tolerated in most patients, and no serious adverse effects have been reported. The drug provides significant advantages over existing competitive therapies, including bimonthly administration and approved use in children.
Host
Reactivity
Human
Applications
ELISA
Conjugation
Canakinumab Biosimilar - Research Grade, ichor.bio, ICH5115
Detects human IL1B
Host
CHO Cells
Reactivity
Human
Applications
Conjugation
Please provide the required information below so that we can quickly source your products.